September 20, 2024
Rose
The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive insulin products and forced patients to pay more.
from NYT > Health https://ift.tt/hrUJjCb
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment